DVAX
DVAX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Recent trades of DVAX by members of U.S. Congress
DVAX Stock Insider Trading Activity
Follow @QuiverQuant for major insider updates
---
Closing Price
Purchase
Sale
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
DVAX Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
DVAX Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in DVAX holdings by institutional investors
Quarterly net insider trading by DVAX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Backtest Start Date
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Subscribe to Quiver Premium for insider trading alerts
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$120,000 Jul 17, 2026 Issue: None
-
$120,000 Apr 20, 2026 Issue: None
-
$120,000 Jan 17, 2026 Issue: None
-
$140,000 Oct 20, 2025 Issue: None
-
$140,000 Jul 18, 2025 Issue: None
-
$100,000 Apr 14, 2025 Issue: None
-
$120,000 Jan 20, 2025 Issue: None
-
$100,000 Oct 18, 2024 Issue: None
-
$110,000 Jul 22, 2024 Issue: None
-
$80,000 Jan 19, 2024 Issue: None
-
$80,000 Oct 20, 2023 Issue: Health Issues
-
$80,000 Jul 14, 2023 Issue: None
-
$90,000 Jan 20, 2023 Issue: None
-
$90,000 Oct 19, 2022 Issue: None
-
$90,000 Jul 20, 2022 Issue: None
-
$120,000 Apr 20, 2022 Issue: Health Issues
-
$50,000 Jan 20, 2022 Issue: HEALTH ISSUES
-
$75,000 Oct 20, 2021 Issue: Pharmacy
-
$75,000 Jul 15, 2021 Issue: Pharmacy
-
$75,000 Apr 15, 2021 Issue: Pharmacy
-
$75,000 Jan 18, 2021 Issue: Pharmacy
-
$75,000 Oct 06, 2020 Issue: Pharmacy
-
$75,000 Oct 06, 2020 Issue: Pharmacy
-
$65,000 Oct 06, 2020 Issue: Pharmacy
-
$45,000 Jan 14, 2020 Issue: Pharmacy
-
$45,000 Oct 07, 2019 Issue: Pharmacy
-
$45,000 Jul 03, 2019 Issue: Pharmacy
-
$45,000 Apr 10, 2019 Issue: Pharmacy
-
$45,000 Jan 18, 2019 Issue: Pharmacy
-
$45,000 Oct 18, 2018 Issue: Pharmacy
-
$45,000 Jul 26, 2018 Issue: Pharmacy
-
$45,000 Apr 30, 2018 Issue: Pharmacy
-
$20,000 Feb 12, 2018 Issue: Pharmacy
-
$45,000 Oct 23, 2017 Issue: Pharmacy
-
$45,000 Jul 20, 2017 Issue: Pharmacy
-
$25,000 Apr 20, 2017 Issue: Pharmacy
-
$20,000 Jan 24, 2017 Issue: Pharmacy
-
$10,000 Oct 19, 2016 Issue: Pharmacy
-
$10,000 Jul 19, 2016 Issue: Pharmacy
-
$10,000 Apr 18, 2016 Issue: Pharmacy
-
$20,000 Oct 21, 2015 Issue: Pharmacy
-
$20,000 Jul 16, 2015 Issue: Pharmacy
-
$20,000 Apr 20, 2015 Issue: Pharmacy
-
$20,000 Jan 14, 2015 Issue: Pharmacy
-
$20,000 Oct 14, 2014 Issue: Pharmacy
-
$20,000 Jul 14, 2014 Issue: Pharmacy
-
$20,000 Jun 02, 2014 Issue: Pharmacy
-
$60,000 Oct 08, 2013 Issue: Pharmacy
-
$20,000 Aug 06, 2013 Issue: Pharmacy
-
$20,000 Aug 06, 2013 Issue: Pharmacy
Former government officials who have lobbied for DVAX
DVAX Estimated quarterly lobbying spending
DVAX Revenue by Segment or Geography
By Segment
By Geography
DVAX Income Statement
DVAX Balance Sheet
DVAX Cash Flow
U.S. Patents
New DVAX patent grants
-
Patent Title: Shingles vaccines comprising a tlr9 agonist Mar. 10, 2026
-
Patent Title: Toll-like receptor antagonist compounds and methods of use Aug. 05, 2025
-
Patent Title: Immunogenicity of a cpg-adjuvanted recombinant plague vaccine Jul. 22, 2025
-
Patent Title: Alkyl chain modified imidazoquinoline tlr7/8 agonist compounds and uses thereof May. 14, 2024
-
Patent Title: Toll-like receptor antagonist compounds and methods of use Nov. 28, 2023
-
Patent Title: Toll-like receptor antagonist compounds and methods of use Jun. 28, 2022
-
Patent Title: Alkyl chain modified imidazoquinoline tlr7/8 agonist compounds and uses thereof Sep. 21, 2021
-
Patent Title: Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof Jul. 28, 2020
-
Patent Title: Branched chimeric compounds, and methods of use thereof Feb. 04, 2020
-
Patent Title: Administration of polynucleotide toll-like receptor 9 agonists for treating cancer Aug. 06, 2019
-
Patent Title: Linear chimeric compounds and methods of use thereof Jul. 16, 2019
-
Patent Title: Methods and compositions for eliciting an immune response against hepatitis b virus Jun. 11, 2019
-
Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Feb. 05, 2019
-
Patent Title: Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung Oct. 30, 2018
-
Patent Title: Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung Jun. 12, 2018
-
Patent Title: Branched and linear chimeric compounds, polynucleotides, uses and methods for preparation thereof Apr. 24, 2018
-
Patent Title: Methods and compositions for eliciting an immune response against hepatitis b virus Feb. 06, 2018
-
Patent Title: Human toll-like receptor inhibitors and methods of use thereof Jan. 16, 2018
-
Patent Title: Methods and compositions for inhibition of immune responses and autoimmunity Oct. 25, 2016
-
Patent Title: Methods and compositions for eliciting an immune response against hepatitis b virus Sep. 27, 2016
-
Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Aug. 23, 2016
-
Patent Title: Methods of treatment using tlr7 and/or tlr9 inhibitors May. 24, 2016
-
Patent Title: Long term disease modification using immunostimulatory oligonucleotides May. 10, 2016
-
Patent Title: Human toll-like receptor inhibitors and methods of use thereof Jan. 05, 2016
-
Patent Title: Transgenic mice expressing human toll-like receptor 8 Jun. 23, 2015
-
Patent Title: Chimeric immunomodulatory compounds and methods of using the same-iv May. 12, 2015
-
Patent Title: Methods and compositions for inhibition of immune responses and autoimmunity Feb. 24, 2015
-
Patent Title: Methods of treatment using tlr7 and/or tlr9 inhibitors Jan. 27, 2015
-
Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Oct. 28, 2014
-
Patent Title: Compositions comprising structurally stable conjugate molecules Oct. 14, 2014
-
Patent Title: Long term disease modification using immunostimulatory oligonucleotides Aug. 26, 2014
-
Patent Title: Methods and compositions for inhibition of innate immune responses and autoimmunity Jun. 24, 2014
-
Patent Title: Biodegradable immunomodulatory formulations and methods for use thereof Mar. 11, 2014
-
Patent Title: Chimeric immunomodulatory compounds and methods of using the same-iv Dec. 03, 2013
-
Patent Title: Immunomodulatory compositions, formulations, and methods for use thereof Nov. 19, 2013
-
Patent Title: Immunomodulatory polynucleotides and methods of using the same Feb. 12, 2013
-
Patent Title: Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein Dec. 18, 2012
-
Patent Title: Long term disease modification using immunostimulatory oligonucleotides Aug. 28, 2012
-
Patent Title: Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences Jul. 24, 2012
-
Patent Title: Chimeric immunomodulatory compounds and methods of using the same-ii Jul. 17, 2012
-
Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Apr. 17, 2012
-
Patent Title: Biodegradable immunomodulatory formulations and methods for use thereof Feb. 28, 2012
-
Patent Title: Chimeric immunomodulatory compounds and methods of using the same—iv Feb. 14, 2012
-
Patent Title: Chimeric immunomodulatory compounds and methods of using the same Aug. 23, 2011
-
Patent Title: Immunomodulatory compositions, methods of making, and methods of use thereof Feb. 08, 2011
-
Patent Title: Chimeric immunomodulatory compounds and methods of using the same—iii Aug. 31, 2010
-
Patent Title: Immunostimulatory sequence oligonucleotides and methods of using the same Jun. 29, 2010
-
Patent Title: Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences Jun. 01, 2010
-
Patent Title: Compositions comprising structurally stable conjugate molecules May. 18, 2010
Government Contracts
Federal grants, loans, and purchases
- $16 2025-09-19 00:00:00 Agency: Department of Justice
- $763,734 2025-06-16 00:00:00 Agency: Department of Health and Human Services
- $379,802 2024-06-27 00:00:00 Agency: Department of Health and Human Services
- $0 2023-09-28 00:00:00 Agency: Department of Veterans Affairs
- $722,422 2023-06-28 00:00:00 Agency: Department of Health and Human Services
- $1,101,843 2022-06-29 00:00:00 Agency: DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)
Government Contracts
Estimated quarterly amount awarded to DVAX from public contracts
DVAX News
Recent insights relating to DVAX
CNBC Recommendations
Recent picks made for DVAX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in DVAX
DVAX Analyst Ratings
DVAX Stock Forecasts
...
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
DVAX Analyst Forecasts
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
Frequently Asked Questions
- Is $DVAX stock a Buy, Sell, or Hold?
- What is the price target for $DVAX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
DVAX Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
Frequently Asked Questions
- Who owns $DVAX stock?
- Who owns the most shares of $DVAX stock?
- What funds own $DVAX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
DVAX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view DVAX Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
About DVAX
No description available
DVAX (DVAX) Historical Stock Prices
DVAX (DVAX) closed at $15.50 on February 9, 2026. Over the past year its adjusted close ranged from $9.36 to $15.72. Daily prices go back to January 2, 2014, 3,043 trading days in all.
- 1 month+0.58%
- 3 months+40.40%
- Year to date+0.78%
- 1 year+17.87%
- 3 years+40.27%
- 5 years+57.84%
- Max-22.11%
See every congressional and insider trade on the DVAX price chart
Quiver Premium charts DVAX's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | 15.49 | 15.50 | 15.49 | 15.50 | 15.50 | 7,106,122 |
| Feb 6, 2026 | 15.49 | 15.50 | 15.49 | 15.50 | 15.50 | 2,009,541 |
| Feb 5, 2026 | 15.50 | 15.50 | 15.49 | 15.49 | 15.49 | 3,634,690 |
| Feb 4, 2026 | 15.48 | 15.59 | 15.47 | 15.51 | 15.51 | 4,483,678 |
| Feb 3, 2026 | 15.46 | 15.49 | 15.46 | 15.48 | 15.48 | 3,434,369 |
| Feb 2, 2026 | 15.48 | 15.50 | 15.48 | 15.49 | 15.49 | 823,266 |
| Jan 30, 2026 | 15.48 | 15.50 | 15.47 | 15.48 | 15.48 | 1,559,096 |
| Jan 29, 2026 | 15.49 | 15.49 | 15.48 | 15.48 | 15.48 | 1,538,001 |
| Jan 28, 2026 | 15.50 | 15.51 | 15.48 | 15.48 | 15.48 | 2,245,727 |
| Jan 27, 2026 | 15.49 | 15.55 | 15.47 | 15.48 | 15.48 | 1,806,305 |
| Jan 26, 2026 | 15.51 | 15.56 | 15.49 | 15.52 | 15.52 | 1,771,194 |
| Jan 23, 2026 | 15.64 | 15.65 | 15.51 | 15.51 | 15.51 | 2,181,390 |
| Jan 22, 2026 | 15.68 | 15.69 | 15.64 | 15.65 | 15.65 | 1,910,836 |
| Jan 21, 2026 | 15.56 | 15.69 | 15.56 | 15.68 | 15.68 | 1,620,788 |
| Jan 20, 2026 | 15.63 | 15.69 | 15.61 | 15.68 | 15.68 | 2,447,933 |
| Jan 16, 2026 | 15.65 | 15.67 | 15.60 | 15.63 | 15.63 | 1,836,270 |
| Jan 15, 2026 | 15.59 | 15.67 | 15.59 | 15.62 | 15.62 | 2,432,746 |
| Jan 14, 2026 | 15.69 | 15.69 | 15.57 | 15.60 | 15.60 | 2,199,303 |
| Jan 13, 2026 | 15.68 | 15.72 | 15.66 | 15.72 | 15.72 | 2,975,849 |
| Jan 12, 2026 | 15.66 | 15.73 | 15.61 | 15.68 | 15.68 | 9,825,994 |
| Jan 9, 2026 | 15.42 | 15.43 | 15.40 | 15.41 | 15.41 | 2,272,806 |
| Jan 8, 2026 | 15.42 | 15.43 | 15.40 | 15.41 | 15.41 | 4,676,762 |
| Jan 7, 2026 | 15.43 | 15.45 | 15.40 | 15.41 | 15.41 | 2,741,651 |
| Jan 6, 2026 | 15.40 | 15.44 | 15.39 | 15.43 | 15.43 | 8,698,326 |
| Jan 5, 2026 | 15.38 | 15.44 | 15.37 | 15.41 | 15.41 | 9,144,420 |
| Jan 2, 2026 | 15.39 | 15.39 | 15.37 | 15.38 | 15.38 | 5,385,510 |
| Dec 31, 2025 | 15.38 | 15.40 | 15.37 | 15.38 | 15.38 | 2,891,628 |
| Dec 30, 2025 | 15.38 | 15.43 | 15.37 | 15.37 | 15.37 | 4,467,455 |
| Dec 29, 2025 | 15.38 | 15.40 | 15.37 | 15.37 | 15.37 | 6,918,889 |
| Dec 26, 2025 | 15.41 | 15.41 | 15.37 | 15.38 | 15.38 | 6,095,632 |
| Dec 24, 2025 | 15.49 | 15.49 | 15.38 | 15.38 | 15.38 | 30,747,058 |
| Dec 23, 2025 | 11.08 | 11.14 | 10.97 | 11.13 | 11.13 | 1,380,843 |
| Dec 22, 2025 | 10.88 | 11.29 | 10.78 | 11.16 | 11.16 | 1,995,382 |
| Dec 19, 2025 | 10.88 | 11.07 | 10.84 | 10.86 | 10.86 | 3,960,494 |
| Dec 18, 2025 | 10.80 | 10.97 | 10.80 | 10.87 | 10.87 | 1,144,656 |
| Dec 17, 2025 | 10.79 | 11.02 | 10.63 | 10.79 | 10.79 | 1,715,164 |
| Dec 16, 2025 | 10.82 | 10.90 | 10.75 | 10.78 | 10.78 | 1,739,333 |
| Dec 15, 2025 | 10.81 | 10.97 | 10.77 | 10.85 | 10.85 | 1,507,379 |
| Dec 12, 2025 | 10.89 | 10.91 | 10.76 | 10.80 | 10.80 | 1,066,655 |
| Dec 11, 2025 | 10.95 | 11.00 | 10.79 | 10.86 | 10.86 | 1,247,049 |
| Dec 10, 2025 | 10.91 | 10.96 | 10.71 | 10.90 | 10.90 | 1,214,427 |
| Dec 9, 2025 | 10.97 | 11.11 | 10.86 | 10.89 | 10.89 | 1,711,313 |
| Dec 8, 2025 | 10.97 | 11.18 | 10.87 | 10.97 | 10.97 | 2,024,666 |
| Dec 5, 2025 | 10.95 | 11.03 | 10.87 | 10.89 | 10.89 | 1,075,684 |
| Dec 4, 2025 | 10.96 | 11.03 | 10.79 | 10.96 | 10.96 | 1,500,922 |
| Dec 3, 2025 | 10.88 | 11.10 | 10.86 | 10.97 | 10.97 | 1,516,664 |
| Dec 2, 2025 | 10.70 | 10.92 | 10.65 | 10.88 | 10.88 | 1,711,820 |
| Dec 1, 2025 | 11.23 | 11.31 | 10.63 | 10.71 | 10.71 | 2,349,098 |
| Nov 28, 2025 | 11.44 | 11.49 | 11.34 | 11.37 | 11.37 | 836,339 |
| Nov 26, 2025 | 11.43 | 11.53 | 11.33 | 11.43 | 11.43 | 1,575,510 |
| Nov 25, 2025 | 11.41 | 11.58 | 11.35 | 11.47 | 11.47 | 1,306,647 |
| Nov 24, 2025 | 11.21 | 11.50 | 11.17 | 11.44 | 11.44 | 2,297,522 |
| Nov 21, 2025 | 10.81 | 11.25 | 10.69 | 11.18 | 11.18 | 1,774,630 |
| Nov 20, 2025 | 11.17 | 11.26 | 10.76 | 10.80 | 10.80 | 2,161,751 |
| Nov 19, 2025 | 11.13 | 11.24 | 10.91 | 11.05 | 11.05 | 1,431,628 |
| Nov 18, 2025 | 11.08 | 11.27 | 11.04 | 11.23 | 11.23 | 1,584,556 |
| Nov 17, 2025 | 11.02 | 11.29 | 11.02 | 11.14 | 11.14 | 1,869,274 |
| Nov 14, 2025 | 10.97 | 11.24 | 10.97 | 11.06 | 11.06 | 1,331,651 |
| Nov 13, 2025 | 11.27 | 11.40 | 11.13 | 11.16 | 11.16 | 1,897,216 |
| Nov 12, 2025 | 11.21 | 11.43 | 11.15 | 11.26 | 11.26 | 2,018,287 |
| Nov 11, 2025 | 11.05 | 11.38 | 10.97 | 11.27 | 11.27 | 2,036,607 |
| Nov 10, 2025 | 10.93 | 11.23 | 10.86 | 11.04 | 11.04 | 1,914,098 |
| Nov 7, 2025 | 10.98 | 11.06 | 10.52 | 10.83 | 10.83 | 2,265,278 |
| Nov 6, 2025 | 10.64 | 11.24 | 10.50 | 10.99 | 10.99 | 4,116,099 |
| Nov 5, 2025 | 9.95 | 10.39 | 9.92 | 10.30 | 10.30 | 2,378,341 |
| Nov 4, 2025 | 10.15 | 10.31 | 10.04 | 10.05 | 10.05 | 2,232,249 |
| Nov 3, 2025 | 10.22 | 10.34 | 10.10 | 10.19 | 10.19 | 1,722,227 |
| Oct 31, 2025 | 10.30 | 10.46 | 10.20 | 10.26 | 10.26 | 1,761,467 |
| Oct 30, 2025 | 10.20 | 10.46 | 10.11 | 10.40 | 10.40 | 1,230,755 |
| Oct 29, 2025 | 10.41 | 10.58 | 10.27 | 10.30 | 10.30 | 1,506,081 |
| Oct 28, 2025 | 10.43 | 10.55 | 10.38 | 10.46 | 10.46 | 903,125 |
| Oct 27, 2025 | 10.41 | 10.59 | 10.39 | 10.49 | 10.49 | 1,114,584 |
| Oct 24, 2025 | 10.23 | 10.40 | 10.18 | 10.38 | 10.38 | 965,245 |
| Oct 23, 2025 | 10.12 | 10.23 | 10.03 | 10.19 | 10.19 | 1,242,978 |
| Oct 22, 2025 | 10.12 | 10.22 | 10.04 | 10.15 | 10.15 | 1,266,810 |
| Oct 21, 2025 | 10.06 | 10.17 | 9.99 | 10.12 | 10.12 | 1,261,872 |
| Oct 20, 2025 | 9.91 | 10.12 | 9.84 | 10.06 | 10.06 | 1,100,439 |
| Oct 17, 2025 | 9.83 | 9.93 | 9.79 | 9.83 | 9.83 | 1,145,571 |
| Oct 16, 2025 | 9.95 | 10.12 | 9.71 | 9.80 | 9.80 | 1,518,685 |
| Oct 15, 2025 | 9.82 | 9.98 | 9.80 | 9.93 | 9.93 | 1,251,454 |
| Oct 14, 2025 | 9.98 | 10.05 | 9.83 | 9.83 | 9.83 | 959,062 |
| Oct 13, 2025 | 9.97 | 10.11 | 9.95 | 10.01 | 10.01 | 911,118 |
| Oct 10, 2025 | 10.32 | 10.36 | 9.96 | 9.96 | 9.96 | 1,291,285 |
| Oct 9, 2025 | 10.18 | 10.38 | 10.11 | 10.35 | 10.35 | 1,431,922 |
| Oct 8, 2025 | 10.15 | 10.31 | 10.14 | 10.18 | 10.18 | 1,392,798 |
| Oct 7, 2025 | 10.15 | 10.30 | 10.07 | 10.14 | 10.14 | 1,414,596 |
| Oct 6, 2025 | 10.13 | 10.21 | 9.95 | 10.14 | 10.14 | 1,393,869 |
| Oct 3, 2025 | 10.15 | 10.18 | 10.02 | 10.10 | 10.10 | 1,240,582 |
| Oct 2, 2025 | 10.31 | 10.34 | 10.00 | 10.10 | 10.10 | 929,644 |
| Oct 1, 2025 | 9.97 | 10.35 | 9.93 | 10.28 | 10.28 | 1,676,618 |
| Sep 30, 2025 | 9.63 | 10.03 | 9.60 | 9.93 | 9.93 | 1,498,163 |
| Sep 29, 2025 | 9.80 | 9.84 | 9.60 | 9.66 | 9.66 | 1,721,017 |
| Sep 26, 2025 | 9.77 | 9.82 | 9.62 | 9.78 | 9.78 | 1,461,224 |
| Sep 25, 2025 | 9.98 | 10.03 | 9.65 | 9.73 | 9.73 | 1,334,591 |
| Sep 24, 2025 | 9.60 | 9.99 | 9.53 | 9.96 | 9.96 | 1,757,328 |
| Sep 23, 2025 | 9.68 | 9.84 | 9.57 | 9.59 | 9.59 | 1,351,150 |
| Sep 22, 2025 | 9.69 | 9.73 | 9.60 | 9.69 | 9.69 | 1,085,426 |
| Sep 19, 2025 | 9.76 | 9.81 | 9.58 | 9.69 | 9.69 | 5,633,420 |
| Sep 18, 2025 | 9.61 | 9.84 | 9.53 | 9.75 | 9.75 | 1,671,244 |
| Sep 17, 2025 | 9.75 | 9.77 | 9.53 | 9.57 | 9.57 | 1,975,794 |
| Sep 16, 2025 | 9.35 | 9.71 | 9.35 | 9.70 | 9.70 | 1,792,952 |
| Sep 15, 2025 | 9.39 | 9.44 | 9.20 | 9.36 | 9.36 | 1,825,940 |
| Sep 12, 2025 | 9.67 | 9.67 | 9.40 | 9.41 | 9.41 | 1,650,058 |
| Sep 11, 2025 | 9.70 | 9.77 | 9.57 | 9.74 | 9.74 | 1,697,467 |
| Sep 10, 2025 | 9.91 | 9.94 | 9.72 | 9.72 | 9.72 | 1,371,416 |
| Sep 9, 2025 | 9.73 | 9.92 | 9.70 | 9.92 | 9.92 | 1,282,730 |
| Sep 8, 2025 | 10.03 | 10.03 | 9.51 | 9.70 | 9.70 | 3,312,511 |
| Sep 5, 2025 | 9.98 | 10.09 | 9.90 | 10.06 | 10.06 | 1,421,967 |
| Sep 4, 2025 | 10.16 | 10.28 | 9.90 | 9.98 | 9.98 | 1,826,384 |
| Sep 3, 2025 | 9.78 | 10.18 | 9.77 | 10.13 | 10.13 | 1,735,787 |
| Sep 2, 2025 | 10.12 | 10.29 | 9.77 | 9.91 | 9.91 | 2,330,972 |
| Aug 29, 2025 | 10.30 | 10.30 | 10.04 | 10.12 | 10.12 | 1,164,891 |
| Aug 28, 2025 | 10.26 | 10.36 | 10.18 | 10.27 | 10.27 | 1,921,873 |
| Aug 27, 2025 | 10.41 | 10.43 | 10.20 | 10.26 | 10.26 | 1,574,341 |
| Aug 26, 2025 | 10.38 | 10.50 | 10.34 | 10.44 | 10.44 | 2,279,904 |
| Aug 25, 2025 | 10.53 | 10.57 | 10.27 | 10.39 | 10.39 | 2,584,146 |
| Aug 22, 2025 | 10.93 | 10.97 | 10.48 | 10.50 | 10.50 | 3,702,698 |
| Aug 21, 2025 | 11.21 | 11.45 | 10.90 | 10.95 | 10.95 | 4,463,614 |
| Aug 20, 2025 | 10.51 | 10.58 | 10.28 | 10.42 | 10.42 | 919,628 |
| Aug 19, 2025 | 10.73 | 10.76 | 10.44 | 10.49 | 10.49 | 940,229 |
| Aug 18, 2025 | 10.83 | 10.96 | 10.72 | 10.76 | 10.76 | 752,421 |
| Aug 15, 2025 | 10.68 | 10.81 | 10.63 | 10.79 | 10.79 | 1,019,773 |
| Aug 14, 2025 | 10.70 | 10.70 | 10.48 | 10.62 | 10.62 | 1,051,597 |
| Aug 13, 2025 | 10.65 | 10.86 | 10.53 | 10.82 | 10.82 | 1,911,247 |
| Aug 12, 2025 | 10.50 | 10.86 | 10.46 | 10.58 | 10.58 | 1,457,420 |
| Aug 11, 2025 | 10.31 | 10.57 | 10.21 | 10.47 | 10.47 | 1,703,721 |
| Aug 8, 2025 | 12.06 | 12.06 | 9.86 | 10.33 | 10.33 | 4,776,516 |
| Aug 7, 2025 | 11.20 | 11.30 | 10.94 | 11.06 | 11.06 | 1,618,504 |
| Aug 6, 2025 | 11.07 | 11.24 | 11.05 | 11.19 | 11.19 | 885,023 |
| Aug 5, 2025 | 11.08 | 11.30 | 11.03 | 11.15 | 11.15 | 1,189,825 |
| Aug 4, 2025 | 10.88 | 11.15 | 10.79 | 11.14 | 11.14 | 1,544,168 |
| Aug 1, 2025 | 10.95 | 11.05 | 10.77 | 10.86 | 10.86 | 1,284,624 |
| Jul 31, 2025 | 11.06 | 11.28 | 10.67 | 10.98 | 10.98 | 1,207,421 |
| Jul 30, 2025 | 11.30 | 11.40 | 11.12 | 11.17 | 11.17 | 800,130 |
| Jul 29, 2025 | 11.33 | 11.34 | 11.09 | 11.19 | 11.19 | 818,325 |
| Jul 28, 2025 | 11.36 | 11.44 | 11.28 | 11.29 | 11.29 | 716,337 |
| Jul 25, 2025 | 11.17 | 11.38 | 11.07 | 11.36 | 11.36 | 779,696 |
| Jul 24, 2025 | 11.35 | 11.48 | 11.14 | 11.16 | 11.16 | 770,244 |
| Jul 23, 2025 | 11.21 | 11.45 | 11.14 | 11.35 | 11.35 | 1,014,778 |
| Jul 22, 2025 | 11.00 | 11.27 | 10.94 | 11.18 | 11.18 | 1,952,191 |
| Jul 21, 2025 | 10.77 | 11.02 | 10.74 | 10.94 | 10.94 | 1,057,378 |
| Jul 18, 2025 | 10.79 | 10.82 | 10.62 | 10.72 | 10.72 | 928,424 |
| Jul 17, 2025 | 10.71 | 10.78 | 10.62 | 10.67 | 10.67 | 852,150 |
| Jul 16, 2025 | 10.50 | 10.72 | 10.46 | 10.67 | 10.67 | 897,515 |
| Jul 15, 2025 | 10.78 | 10.78 | 10.38 | 10.44 | 10.44 | 1,512,864 |
| Jul 14, 2025 | 10.66 | 10.78 | 10.50 | 10.74 | 10.74 | 1,334,054 |
| Jul 11, 2025 | 10.72 | 10.88 | 10.55 | 10.58 | 10.58 | 3,840,929 |
| Jul 10, 2025 | 10.77 | 10.99 | 10.74 | 10.90 | 10.90 | 1,295,201 |
| Jul 9, 2025 | 10.69 | 10.90 | 10.64 | 10.81 | 10.81 | 2,207,560 |
| Jul 8, 2025 | 10.27 | 10.73 | 10.23 | 10.59 | 10.59 | 1,896,558 |
| Jul 7, 2025 | 10.19 | 10.43 | 10.11 | 10.30 | 10.30 | 1,844,869 |
| Jul 3, 2025 | 10.13 | 10.30 | 10.12 | 10.27 | 10.27 | 511,141 |
| Jul 2, 2025 | 10.03 | 10.24 | 9.97 | 10.16 | 10.16 | 1,431,192 |
| Jul 1, 2025 | 9.87 | 10.38 | 9.79 | 10.06 | 10.06 | 1,332,505 |
| Jun 30, 2025 | 9.89 | 10.13 | 9.81 | 9.92 | 9.92 | 1,452,564 |
| Jun 27, 2025 | 9.94 | 10.03 | 9.77 | 9.91 | 9.91 | 4,832,262 |
| Jun 26, 2025 | 9.85 | 9.94 | 9.76 | 9.94 | 9.94 | 936,125 |
| Jun 25, 2025 | 9.91 | 9.91 | 9.74 | 9.86 | 9.86 | 1,268,659 |
| Jun 24, 2025 | 9.88 | 9.99 | 9.73 | 9.91 | 9.91 | 1,125,836 |
| Jun 23, 2025 | 10.00 | 10.04 | 9.65 | 9.77 | 9.77 | 1,318,548 |
| Jun 20, 2025 | 10.37 | 10.38 | 9.91 | 9.99 | 9.99 | 5,233,687 |
| Jun 18, 2025 | 9.99 | 10.68 | 9.89 | 10.30 | 10.30 | 3,059,426 |
| Jun 17, 2025 | 10.11 | 10.31 | 9.98 | 9.99 | 9.99 | 1,955,655 |
| Jun 16, 2025 | 10.29 | 10.45 | 10.14 | 10.17 | 10.17 | 1,622,166 |
| Jun 13, 2025 | 10.27 | 10.42 | 10.21 | 10.27 | 10.27 | 1,120,118 |
| Jun 12, 2025 | 10.07 | 10.47 | 10.06 | 10.40 | 10.40 | 1,073,508 |
| Jun 11, 2025 | 10.42 | 10.48 | 10.18 | 10.18 | 10.18 | 1,301,870 |
| Jun 10, 2025 | 10.31 | 10.46 | 10.11 | 10.43 | 10.43 | 1,524,505 |
| Jun 9, 2025 | 10.23 | 10.49 | 10.15 | 10.28 | 10.28 | 1,369,142 |
| Jun 6, 2025 | 10.09 | 10.25 | 10.00 | 10.24 | 10.24 | 1,408,814 |
| Jun 5, 2025 | 9.81 | 10.04 | 9.80 | 9.95 | 9.95 | 1,259,805 |
| Jun 4, 2025 | 9.98 | 10.12 | 9.75 | 9.89 | 9.89 | 1,439,541 |
| Jun 3, 2025 | 9.85 | 10.04 | 9.68 | 10.01 | 10.01 | 1,731,566 |
| Jun 2, 2025 | 9.81 | 10.00 | 9.74 | 9.84 | 9.84 | 1,616,426 |
| May 30, 2025 | 9.72 | 9.87 | 9.59 | 9.79 | 9.79 | 1,937,332 |
| May 29, 2025 | 9.60 | 9.85 | 9.50 | 9.76 | 9.76 | 2,053,593 |
| May 28, 2025 | 9.83 | 9.83 | 9.49 | 9.50 | 9.50 | 2,306,904 |
| May 27, 2025 | 9.90 | 9.94 | 9.78 | 9.78 | 9.78 | 1,332,644 |
| May 23, 2025 | 9.70 | 9.84 | 9.61 | 9.80 | 9.80 | 1,345,686 |
| May 22, 2025 | 9.85 | 10.05 | 9.81 | 9.82 | 9.82 | 1,406,644 |
| May 21, 2025 | 10.31 | 10.35 | 9.87 | 9.90 | 9.90 | 2,519,115 |
| May 20, 2025 | 9.83 | 10.44 | 9.79 | 10.42 | 10.42 | 2,364,513 |
| May 19, 2025 | 9.62 | 9.88 | 9.62 | 9.83 | 9.83 | 1,518,888 |
| May 16, 2025 | 9.51 | 9.81 | 9.45 | 9.67 | 9.67 | 1,573,606 |
| May 15, 2025 | 9.42 | 9.55 | 9.34 | 9.51 | 9.51 | 1,384,658 |
| May 14, 2025 | 9.59 | 9.67 | 9.22 | 9.40 | 9.40 | 3,500,961 |
| May 13, 2025 | 9.85 | 9.90 | 9.51 | 9.62 | 9.62 | 1,736,399 |
| May 12, 2025 | 9.54 | 10.16 | 9.53 | 9.85 | 9.85 | 4,464,078 |
| May 9, 2025 | 9.73 | 9.88 | 9.38 | 9.41 | 9.41 | 2,027,654 |
| May 8, 2025 | 9.62 | 9.90 | 9.28 | 9.69 | 9.69 | 3,195,280 |
| May 7, 2025 | 10.55 | 10.79 | 9.62 | 9.72 | 9.72 | 6,232,173 |
| May 6, 2025 | 11.11 | 11.21 | 10.88 | 10.92 | 10.92 | 3,491,262 |
| May 5, 2025 | 11.28 | 11.43 | 11.20 | 11.26 | 11.26 | 1,512,429 |
| May 2, 2025 | 11.47 | 11.61 | 11.23 | 11.33 | 11.33 | 1,750,419 |
| May 1, 2025 | 11.72 | 11.72 | 11.38 | 11.48 | 11.48 | 1,581,561 |
| Apr 30, 2025 | 11.52 | 11.77 | 11.41 | 11.75 | 11.75 | 2,597,539 |
| Apr 29, 2025 | 11.27 | 11.64 | 11.13 | 11.55 | 11.55 | 2,374,436 |
| Apr 28, 2025 | 10.88 | 11.28 | 10.82 | 11.27 | 11.27 | 1,806,780 |
| Apr 25, 2025 | 10.81 | 10.91 | 10.68 | 10.82 | 10.82 | 1,508,173 |
| Apr 24, 2025 | 10.74 | 11.10 | 10.68 | 10.90 | 10.90 | 2,410,777 |
| Apr 23, 2025 | 10.80 | 11.19 | 10.70 | 10.77 | 10.77 | 2,406,343 |
| Apr 22, 2025 | 10.54 | 10.79 | 10.31 | 10.72 | 10.72 | 2,536,642 |
| Apr 21, 2025 | 10.30 | 10.49 | 10.04 | 10.44 | 10.44 | 2,714,986 |
| Apr 17, 2025 | 10.61 | 10.79 | 10.26 | 10.31 | 10.31 | 2,950,857 |
| Apr 16, 2025 | 11.30 | 11.38 | 10.59 | 10.65 | 10.65 | 2,693,931 |
| Apr 15, 2025 | 11.38 | 11.47 | 11.27 | 11.41 | 11.41 | 2,188,287 |
| Apr 14, 2025 | 11.39 | 11.47 | 11.19 | 11.44 | 11.44 | 2,283,732 |
| Apr 11, 2025 | 11.02 | 11.40 | 10.84 | 11.25 | 11.25 | 2,119,204 |
| Apr 10, 2025 | 11.88 | 11.90 | 10.86 | 10.97 | 10.97 | 4,842,375 |
| Apr 9, 2025 | 11.48 | 12.25 | 11.45 | 12.03 | 12.03 | 8,355,520 |
| Apr 8, 2025 | 12.63 | 12.80 | 11.64 | 11.75 | 11.75 | 4,461,489 |
| Apr 7, 2025 | 12.11 | 12.92 | 12.09 | 12.49 | 12.49 | 2,481,059 |
| Apr 4, 2025 | 12.74 | 12.87 | 12.49 | 12.65 | 12.65 | 2,341,525 |
| Apr 3, 2025 | 12.77 | 13.02 | 12.71 | 12.85 | 12.85 | 2,527,814 |
| Apr 2, 2025 | 12.62 | 13.03 | 12.57 | 12.87 | 12.87 | 1,688,905 |
| Apr 1, 2025 | 12.95 | 12.97 | 12.63 | 12.71 | 12.71 | 1,822,173 |
| Mar 31, 2025 | 13.43 | 13.46 | 12.92 | 12.97 | 12.97 | 2,980,147 |
| Mar 28, 2025 | 13.72 | 13.79 | 13.53 | 13.68 | 13.68 | 1,368,935 |
| Mar 27, 2025 | 13.64 | 13.91 | 13.55 | 13.72 | 13.72 | 1,213,632 |
| Mar 26, 2025 | 14.03 | 14.08 | 13.54 | 13.58 | 13.58 | 1,318,564 |
| Mar 25, 2025 | 13.77 | 14.01 | 13.74 | 13.98 | 13.98 | 1,540,152 |
| Mar 24, 2025 | 13.95 | 14.07 | 13.75 | 13.84 | 13.84 | 1,401,992 |
| Mar 21, 2025 | 13.65 | 13.84 | 13.56 | 13.82 | 13.82 | 3,366,154 |
| Mar 20, 2025 | 13.57 | 13.74 | 13.53 | 13.62 | 13.62 | 1,299,303 |
| Mar 19, 2025 | 13.90 | 13.99 | 13.59 | 13.64 | 13.64 | 3,029,077 |
| Mar 18, 2025 | 13.60 | 13.93 | 13.46 | 13.90 | 13.90 | 2,109,205 |
| Mar 17, 2025 | 13.83 | 13.90 | 13.60 | 13.63 | 13.63 | 1,553,744 |
| Mar 14, 2025 | 13.66 | 14.01 | 13.66 | 13.87 | 13.87 | 2,531,094 |
| Mar 13, 2025 | 13.78 | 13.91 | 13.64 | 13.69 | 13.69 | 1,075,736 |
| Mar 12, 2025 | 13.74 | 13.89 | 13.65 | 13.74 | 13.74 | 2,785,598 |
| Mar 11, 2025 | 14.33 | 14.39 | 13.78 | 13.79 | 13.79 | 3,462,851 |
| Mar 10, 2025 | 14.26 | 14.56 | 14.26 | 14.39 | 14.39 | 2,669,844 |
| Mar 7, 2025 | 14.52 | 14.63 | 14.22 | 14.40 | 14.40 | 2,993,528 |
| Mar 6, 2025 | 14.17 | 14.43 | 13.89 | 14.34 | 14.34 | 17,763,058 |
| Mar 5, 2025 | 13.89 | 14.11 | 13.81 | 14.01 | 14.01 | 1,451,669 |
| Mar 4, 2025 | 13.47 | 13.99 | 13.39 | 13.88 | 13.88 | 2,478,211 |
| Mar 3, 2025 | 13.83 | 13.92 | 13.47 | 13.53 | 13.53 | 2,006,556 |
| Feb 28, 2025 | 13.63 | 13.81 | 13.51 | 13.79 | 13.79 | 1,234,640 |
| Feb 27, 2025 | 13.60 | 13.93 | 13.54 | 13.58 | 13.58 | 1,416,852 |
| Feb 26, 2025 | 13.50 | 13.85 | 13.42 | 13.69 | 13.69 | 2,211,678 |
| Feb 25, 2025 | 13.38 | 13.69 | 13.36 | 13.41 | 13.41 | 1,783,040 |
| Feb 24, 2025 | 13.20 | 13.53 | 13.15 | 13.42 | 13.42 | 2,027,056 |
| Feb 21, 2025 | 13.83 | 14.05 | 13.29 | 13.33 | 13.33 | 2,869,832 |
| Feb 20, 2025 | 13.08 | 13.35 | 13.02 | 13.33 | 13.33 | 2,024,765 |
| Feb 19, 2025 | 12.90 | 13.38 | 12.76 | 13.09 | 13.09 | 2,890,285 |
| Feb 18, 2025 | 12.74 | 13.04 | 12.74 | 12.93 | 12.93 | 1,516,110 |
| Feb 14, 2025 | 12.66 | 12.90 | 12.55 | 12.82 | 12.82 | 924,411 |
| Feb 13, 2025 | 12.67 | 12.88 | 12.53 | 12.69 | 12.69 | 1,622,244 |
| Feb 12, 2025 | 12.48 | 12.49 | 12.10 | 12.45 | 12.45 | 1,950,833 |
| Feb 11, 2025 | 12.05 | 12.70 | 11.81 | 12.70 | 12.70 | 3,330,424 |
| Feb 10, 2025 | 13.03 | 13.34 | 13.03 | 13.20 | 13.20 | 1,079,022 |
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
Need daily prices for every ticker, in code?
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver API
DVAX Executive Compensation
We estimate that -- received a compensation of -- in --, making them the highest paid executive at DVAX, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|